{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.23","value":"-0.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"87"}],"units":"Participants"}],"title":"Cycle 1, Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.24","value":"-0.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"82"}],"units":"Participants"}],"title":"Cycle 2, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.20","value":"-1.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"85"}],"units":"Participants"}],"title":"Cycle 3, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.32","value":"-1.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"}],"units":"Participants"}],"title":"Cycle 5, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.46","value":"-1.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"71"}],"units":"Participants"}],"title":"Cycle 7, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.50","value":"-1.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"65"}],"units":"Participants"}],"title":"Cycle 9, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.36","value":"-1.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"67"}],"units":"Participants"}],"title":"Cycle 11, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.65","value":"-1.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"56"}],"units":"Participants"}],"title":"Cycle 14, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.41","value":"-1.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"56"}],"units":"Participants"}],"title":"Cycle 17, Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"87"}],"units":"Participants"}],"description":"The PGIS is a single-item scale that assesses a participant's perception of disease symptoms at a point in time. Scores range from 0 to 4 points, with higher values representing worse symptom outcomes. It is widely used to evaluate a participant's overall sense of whether a treatment has been beneficial. Each cycle is 28 days long.","dispersionType":"Standard Deviation","groups":[{"description":"Avapritinib was administered once daily as an immediate-release tablet, orally, in 28-day cycles.","id":"OG000","title":"Avapritinib"}],"paramType":"MEAN","populationDescription":"Safety Population: all participants who received ≥1 dose of avapritinib. Here, 'Number Analyzed' signifies those participants evaluable for this outcome measure at the specified timepoint.","reportingStatus":"POSTED","timeFrame":"Baseline, Cycle 1, Day 15 and Day 1 of Cycle 2, Cycle 3, Cycle 5, Cycle 7, Cycle 9, Cycle 11, Cycle 14, and Cycle 17 (28 days/cycle)","title":"Change From Baseline in Patient's Global Impression of Symptom Severity (PGIS)","type":"SECONDARY","unitOfMeasure":"Score on a Scale"}